DUBLIN – Argenx SE passed a critical milestone in its immuno-oncology alliance with Abbvie Inc., by delivering an IND package for ARGX-115, its first-in-class antibody directed at glycoprotein A repetitions predominant (GARP), a cell-surface docking receptor that modulates the activity of the immunosuppressive cytokine transforming growth factor beta (TGF-beta). Abbvie, of North Chicago, has now exercised an option on the program, in which it originally obtained an interest two and a half years ago. (See BioWorld Today, April 22, 2016.)